- Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call TranscriptOct 11, 2023
- Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 15, 2023
- Tempest Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Tempest Therapeutics Inc To Discuss Phase 1b/2 Combination Study of TPST-1120 in First-Line HCC Data Call TranscriptApr 28, 2023
- Tempest Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2022
- Tempest Therapeutics Inc At ASCO Call TranscriptJun 05, 2022
- Millendo Therapeutics Inc And Tempest Therapeutics Inc Merger - M&A Call TranscriptMar 29, 2021
Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve Bersey. I'm an equity research associate here at H.C. Wainwright.
So now, I'd like to welcome Tempest Therapeutics.
Sam Whiting, Chief Medical Officer at Tempest. Tempest would like to thank H.C. Wainwright for the opportunity to present at the 25th Annual Investment Conference. Tempest is a publicly traded company, and I will be making forward-looking statements. Please see our most recent SEC filings.
Tempest Therapeutics is a small but experienced biotech company that exemplifies a diversified opportunity in the oncology space. We have multiple programs, spanning from randomized Phase 2 data in a globally relevant indication in the first-line setting down to novel preclinical programs that are still undisclosed in order to maintain our development advantage.
Our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)